Compare Cassava Sciences Inc (FLNA) vs Grab Holdings Ltd. (GRAB) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

GRAB trades at $3.715, down 2.24% today, with a bullish technical signal from moving averages. The company achieved profitability in 2025 with $268M net income and 7.95% margin, showing significant improvement from previous losses. Revenue grew to $3.37B in 2025, with strong analyst consensus of 11 buys versus 1 sell. Recent news includes CEO share sales and Uber CEO's board departure, creating some investor uncertainty despite positive earnings beats.

GRAB presents a compelling turnaround story with recent profitability and strong growth prospects in Southeast Asian markets. The stock trades at a discount to the $5.45 consensus target, offering 47% upside potential. Key risks include competitive pressures, execution challenges in expanding financial services, and insider selling activity. The company's improving cash flow and debt management support the bullish analyst outlook.